Europe Laboratory Developed Tests Market Size, Share & Trends Analysis Report By Technology (Immunoassay, Molecular Diagnostics), By Application (Oncology, Immunology, Cardiology), And Segment Forecasts, 2024

The Europe laboratory developed tests market size is anticipated to reach USD 6.4 billion by 2030 and is projected to grow at a CAGR of 7.9% from 2024 to 2030, according to a new report by Grand View Research, Inc. The increasing demand for personalized medication, rising prevalence of cancer, and the growing demand for IVD tests currently unavailable in the market are the major factors contributing to the market growth. The 2.3% rise in a number of cancer cases in Europe in 2022, as compared to 2020, to reach a number of around 2.74 million is a major healthcare concern.

The increasing number of deaths caused by non-communicable diseases such as ischemic heart disease, stroke, Alzheimer's disease and other dementia highlights the need for early disease detection. Moreover, diabetes, one more type of non-communicable disease, is a global threat and has also affected Europe, with around 60 million cases across the region. Furthermore, the rising healthcare costs and common medicines not being effective in treating large numbers of patients have led to opting for the option of personalized medication.

Government-sponsored initiatives, such as the European PANCAID and PANCAIM projects, are aiding in the diagnosis and treatment of cancer. The amendments in European in-vitro medical devices regulations in 2022 have relaxed the conditions to be met by health institutions making laboratory developed tests, also known as in-house devices placing on the market and put into service. The launch of the European Partnership for Personalised Medicine (EP PerMed) in 2023 is anticipated to boost research in European precision medicine, increasing the demand for R&D and adoption of laboratory developed tests, driving the market growth in Europe.

Europe Laboratory Developed Tests Market Report Highlights:

Based on technology, the molecular diagnostics segment led the market with a largest revenue share of 26% in 2023, owing to its prominent applications in disease diagnosis at gene level
Based on application, the nutritional and metabolic disease application segment is expected to grow at the fastest CAGR over the forecast period
Based on application, the oncology segment held the market with the largest revenue share of 21% in 2023, owing to the rising incidence in the region. Factors such as sedentary lifestyle, increasing incidences of smoking, and lack of exercise are contributing to the growing prevalence of cancer and metabolic diseases
In November 2023, F. Hoffmann-La Roche Ltd launched its next generation qPCR system LightCycler PRO. This system is expected to help testing patients for cancer, infectious diseases, and other public health challenges

Product Code: GVR-4-68040-198-3

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope
1.2. Segment Definitions
- 1.2.1. Technology
- 1.2.2. Application
- 1.2.3. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR's internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
1.5. Information or Data Analysis
- 1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Volume price analysis (Model 2)
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
- 2.2.1. Technology outlook
- 2.2.2. Application outlook
2.3. Competitive Insights

Chapter 3. Europe Laboratory Developed Tests Market Variables, Trends & Scope

3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.2. Market restraint analysis
3.3. Europe Laboratory Developed Tests Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
  - 3.3.1.1. Supplier power
  - 3.3.1.2. Buyer power
  - 3.3.1.3. Substitution threat
  - 3.3.1.4. Threat of new entrant
  - 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
  - 3.3.2.1. Political landscape
  - 3.3.2.2. Technological landscape
  - 3.3.2.3. Economic landscape

Chapter 4. Europe Laboratory Developed Tests Market: Technology Estimates & Trend Analysis

4.1. Technology Market Share, 2023 & 2030
4.2. Segment Dashboard
4.3. Europe Laboratory Developed Tests Market by Technology Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 4.4.1. Immunoassays
  - 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.4.2. Hematology and coagulation
  - 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.4.3. Molecular diagnostics
  - 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.4.4. Microbiology
  - 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.4.5. Clinical Chemistry
  - 4.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.4.6. Histology/cytology
  - 4.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.4.7. Flow cytometry
  - 4.4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.4.8. Mass spectrometry
  - 4.4.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.4.9. Others
  - 4.4.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Europe Laboratory Developed Tests Market: Application Estimates & Trend Analysis

5.1. Application Market Share, 2023 & 2030
5.2. Segment Dashboard
5.3. Europe Laboratory Developed Tests Market by Application Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 5.4.1. Oncology
  - 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  - 5.4.1.2. Companion diagnostics
  - 5.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  - 5.4.1.3. Genomics sequencing and others
  - 5.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.4.2. Genetic disorders/inherited disease
  - 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.4.3. Infectious and parasitic diseases
  - 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.4.4. Immunology
  - 5.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.4.5. Endocrine
  - 5.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.4.6. Nutritional and metabolic diseases
  - 5.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.4.7. Cardiology
  - 5.4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.4.8. Mental/behavioural disorders
  - 5.4.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.4.9. Pediatrics-specific testing
  - 5.4.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.4.10. Hematology/general blood testing
  - 5.4.10.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.4.11. Body fluids analysis
  - 5.4.11.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.4.12. Toxicology
  - 5.4.12.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.4.13. Other diseases
  - 5.4.13.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Europe Laboratory Developed Tests Market: Country Estimates & Trend Analysis

6.1. Europe Market Share Analysis, 2023 & 2030
6.2. Europe Market Dashboard
6.3. Europe Market Snapshot
6.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
6.5. Europe
- 6.5.1. UK
  - 6.5.1.1. Key country dynamics
  - 6.5.1.2. Regulatory framework/ reimbursement structure
  - 6.5.1.3. Competitive scenario
  - 6.5.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
- 6.5.2. Germany
  - 6.5.2.1. Key country dynamics
  - 6.5.2.2. Regulatory framework/ reimbursement structure
  - 6.5.2.3. Competitive scenario
  - 6.5.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
- 6.5.3. France
  - 6.5.3.1. Key country dynamics
  - 6.5.3.2. Regulatory framework/ reimbursement structure
  - 6.5.3.3. Competitive scenario
  - 6.5.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
- 6.5.4. Italy
  - 6.5.4.1. Key country dynamics
  - 6.5.4.2. Regulatory framework/ reimbursement structure
  - 6.5.4.3. Competitive scenario
  - 6.5.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
- 6.5.5. Spain
  - 6.5.5.1. Key country dynamics
  - 6.5.5.2. Regulatory framework/ reimbursement structure
  - 6.5.5.3. Competitive scenario
  - 6.5.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
- 6.5.6. Norway
  - 6.5.6.1. Key country dynamics
  - 6.5.6.2. Regulatory framework/ reimbursement structure
  - 6.5.6.3. Competitive scenario
  - 6.5.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
- 6.5.7. Sweden
  - 6.5.7.1. Key country dynamics
  - 6.5.7.2. Regulatory framework/ reimbursement structure
  - 6.5.7.3. Competitive scenario
  - 6.5.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
- 6.5.8. Denmark
  - 6.5.8.1. Key country dynamics
  - 6.5.8.2. Regulatory framework/ reimbursement structure
  - 6.5.8.3. Competitive scenario
  - 6.5.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Company/Competition Categorization
7.3. Vendor Landscape
- 7.3.1. List of key distributors and channel partners
- 7.3.2. Key customers
- 7.3.3. Key company heat map analysis, 2023
7.4. Company Profiles
- 7.4.1. Abbott
  - 7.4.1.1. Company overview
  - 7.4.1.2. Financial performance
  - 7.4.1.3. Product benchmarking
  - 7.4.1.4. Strategic initiatives
- 7.4.2. Guardant Health
  - 7.4.2.1. Company overview
  - 7.4.2.2. Financial performance
  - 7.4.2.3. Product benchmarking
  - 7.4.2.4. Strategic initiatives
- 7.4.3. Siemens Healthineers AG
  - 7.4.3.1. Company overview
  - 7.4.3.2. Financial performance
  - 7.4.3.3. Product benchmarking
  - 7.4.3.4. Strategic initiatives
- 7.4.4. Quest Diagnostics
  - 7.4.4.1. Company overview
  - 7.4.4.2. Financial performance
  - 7.4.4.3. Product benchmarking
  - 7.4.4.4. Strategic initiatives
- 7.4.5. Qiagen
  - 7.4.5.1. Company overview
  - 7.4.5.2. Financial performance
  - 7.4.5.3. Product benchmarking
  - 7.4.5.4. Strategic initiatives
- 7.4.6. Eurofins Scientific
  - 7.4.6.1. Company overview
  - 7.4.6.2. Financial performance
  - 7.4.6.3. Product benchmarking
  - 7.4.6.4. Strategic initiatives
- 7.4.7. Illumina, Inc.
  - 7.4.7.1. Company overview
  - 7.4.7.2. Financial performance
  - 7.4.7.3. Product benchmarking
  - 7.4.7.4. Strategic initiatives
- 7.4.8. F.Hoffmann-La Roche Ltd
  - 7.4.8.1. Company overview
  - 7.4.8.2. Financial performance
  - 7.4.8.3. Product benchmarking
  - 7.4.8.4. Strategic initiatives
- 7.4.9. SVAR life sciences
  - 7.4.9.1. Company overview
  - 7.4.9.2. Financial performance
  - 7.4.9.3. Product benchmarking
  - 7.4.9.4. Strategic initiatives
- 7.4.10. Biomerieux
  - 7.4.10.1. Company overview
  - 7.4.10.2. Financial performance
  - 7.4.10.3. Product benchmarking
  - 7.4.10.4. Strategic initiatives
- 7.4.11. BD
  - 7.4.11.1. Company overview
  - 7.4.11.2. Financial performance
  - 7.4.11.3. Product benchmarking
  - 7.4.11.4. Strategic initiatives

Product Code: GVR-4-68040-198-3

List of Tables

Table 1 List of abbreviations
Table 2 Europe laboratory developed tests market, by country, 2018 - 2030 (USD Million)
Table 3 Europe laboratory developed tests market, by technology, 2018 - 2030 (USD Million)
Table 4 Europe laboratory developed tests, by application, 2018 - 2030 (USD Million)
Table 5 Germany laboratory developed tests market, by technology, 2018 - 2030 (USD Million)
Table 6 Germany laboratory developed tests market, by application, 2018 - 2030 (USD Million)
Table 7 UK laboratory developed tests market, by technology, 2018 - 2030 (USD Million)
Table 8 UK laboratory developed tests market, by application, 2018 - 2030 (USD Million)
Table 9 France laboratory developed tests market, by technology, 2018 - 2030 (USD Million)
Table 10 France laboratory developed tests market, by application, 2018 - 2030 (USD Million)
Table 11 Italy laboratory developed tests market, by technology, 2018 - 2030 (USD Million)
Table 12 Italy laboratory developed tests market, by application, 2018 - 2030 (USD Million)
Table 13 Spain laboratory developed tests market, by technology, 2018 - 2030 (USD Million)
Table 14 Spain laboratory developed tests market, by application, 2018 - 2030 (USD Million)
Table 15 Denmark laboratory developed tests market, by technology, 2018 - 2030 (USD Million)
Table 16 Denmark laboratory developed tests market, by application, 2018 - 2030 (USD Million)
Table 17 Sweden laboratory developed tests market, by technology, 2018 - 2030 (USD Million)
Table 18 Sweden laboratory developed tests market, by application, 2018 - 2030 (USD Million)
Table 19 Norway laboratory developed tests market, by technology, 2018 - 2030 (USD Million)
Table 20 Norway laboratory developed tests market, by application, 2018 - 2030 (USD Million)

List of Figures

Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Primary interviews in Europe
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Europe laboratory developed tests: market outlook
Fig. 10 Europe Laboratory developed tests competitive insights
Fig. 11 Parent market outlook
Fig. 12 Related/ancillary market outlook
Fig. 13 Penetration and growth prospect mapping
Fig. 14 Europe Laboratory developed tests market driver impact
Fig. 15 Europe Laboratory developed tests market restraint impact
Fig. 16 Europe Laboratory developed tests market strategic initiatives analysis
Fig. 17 Europe Laboratory developed tests market: Technology movement analysis
Fig. 18 Europe Laboratory developed tests market: Technology outlook and key takeaways
Fig. 19 Immunoassays market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 20 Hematology and coagulation estimates and forecast, 2018 - 2030 (USD Million)
Fig. 21 Molecular diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 22 Microbiology estimates and forecast, 2018 - 2030 (USD Million)
Fig. 23 Clinical chemistry market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 24 Histology/cytology estimates and forecast, 2018 - 2030 (USD Million)
Fig. 25 Flow cytometry estimates and forecast, 2018 - 2030 (USD Million)
Fig. 26 Mass spectrometry estimates and forecast, 2018 - 2030 (USD Million)
Fig. 27 Others estimates and forecast, 2018 - 2030 (USD Million)
Fig. 28 Europe Laboratory developed tests market: application movement analysis
Fig. 29 Europe Laboratory developed tests market: application outlook and key takeaways
Fig. 30 Oncology market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 31 Genetic disorders/inherited disease market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 32 Infectious and parasitic diseases market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 33 Immunology market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 34 Endocrine market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 35 Nutritional and metabolic diseases market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 36 Cardiology market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 37 Mental/behavioral disorder market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 38 Pediatrics-specific tests market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 39 Hematology/general blood testing market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 40 Body fluid analysis market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 41 Toxicology market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 42 Other diseases market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 43 Europe
Fig. 44 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 45 UK
Fig. 46 UK market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 47 Germany
Fig. 48 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 49 France
Fig. 50 France market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 51 Italy
Fig. 52 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 53 Spain
Fig. 54 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 55 Denmark
Fig. 56 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 57 Sweden
Fig. 58 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 59 Norway
Fig. 60 Norway market estimates and forecasts, 2018 - 2030 (USD Million)

Europe Laboratory Developed Tests Market Size, Share & Trends Analysis Report By Technology (Immunoassay, Molecular Diagnostics), By Application (Oncology, Immunology, Cardiology), And Segment Forecasts, 2024 - 2030

Description

Table of Contents

List of Tables

Europe Laboratory Developed Tests Market Growth & Trends:

Europe Laboratory Developed Tests Market Report Highlights:

Table of Contents

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Europe Laboratory Developed Tests Market Variables, Trends & Scope

Chapter 4. Europe Laboratory Developed Tests Market: Technology Estimates & Trend Analysis

Chapter 5. Europe Laboratory Developed Tests Market: Application Estimates & Trend Analysis

Chapter 6. Europe Laboratory Developed Tests Market: Country Estimates & Trend Analysis

Chapter 7. Competitive Landscape

List of Tables

List of Figures